Various supply-chain resilience measures are needed to ensure U.S. drug production before the next pandemic or other natural disaster, a National Academy of Sciences, Engineering and Medicine (NASEM) expert panel…

Gilead Sciences is touting a phase 3 win for its drug-antibody conjugate Trodelvy (sacituzumab govitecan-hziy), saying it significantly improved progression-free survival in women with metastatic, treatment-resistant breast cancer. Source: Drug…

The FDA has approved GlaxoSmithKline’s blockbuster cancer drug Opdivo (nivolumab) in combination with chemotherapy for adult patients with resectable nonsmall-cell lung cancer (NSCLC). It is the first approved neoadjuvant treatment…

Novavax said it has finally put to bed manufacturing issues that might delay the FDA from authorizing its COVID-19 vaccine. Source: Drug Industry Daily

A bill to initiate a prescription drug affordability board is making its way through Washington statehouses. Source: Drug Industry Daily

The U.S. pharmaceutical industry had 274 drug recalls in 2021, the lowest number in five years. The industry saw 344 recalls in 2020. Source: Drug Industry Daily

Eli Lilly’s Olumiant (baricitinib), a powerful anti-inflammatory used to treat rheumatoid arthritis, has once again proven its mettle against COVID-19. Source: Drug Industry Daily

Almost a year after admitting it manipulated safety data for its anemia drug roxadustat, Fibrogen has disclosed that the Securities and Exchange Commission (SEC) is investigating its actions. Source: Drug…

The nonprofit generic drugmaker Civica said that it’s going to manufacture three different insulin biosimilars that, if approved, will be distributed at prices that are “significantly lower” than the cost…

AstraZeneca’s and Sanofi’s investigational long-acting antibody aimed at infants with respiratory syncytial virus (RSV) had positive results in its phase 3 trial, making it the first potential immunization to show…